Reprogramming tumor-associated macrophages via ID3 mRNA delivery for enhanced immunotherapy in pancreatic cancer
Journal of Controlled Release · 2026-12 · 400 · 115472
DOI: 10.1016/j.jconrel.2026.115472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-12. Verfasst von Wenjing Zhou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Functional Nucleic Acids for Basic and Clinical Application, Hangzhou Institute of Medicine (HIM…. Die Arbeit nennt 66 Literaturangaben. Gefördert von: Key Research and Development Program of Zhejiang Province, National Natural Science Foundation of China, Zhejiang Province Natural Science Foundation.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) features a profoundly immunosuppressive tumor microenvironment dominated by tumor-associated macrophages (TAMs), which facilitate immune evasion and compromise immunotherapeutic efficacy. The interaction between signal regulatory protein α (SIRPα) on macrophages and cluster of differentiation 47 (CD47) on tumor cells delivers a "don't-eat-me" signal that inhibits the phagocytosis of tumor cells by macrophages. Here, we present a macrophage-directed mRNA delivery strategy to reprogram TAMs in PDAC. Lipid nanoparticles (LNPs) were engineered to deliver inhibitor of DNA binding 3 (ID3) mRNA, whose expression was associated with reduced SIRPα expression and pro-inflammatory macrophage reprogramming. To promote preferential uptake by TAMs, mannose-modified LNPs (MLNPs) were developed by exploiting elevated CD206 expression on these cells. In an orthotopic PDAC model, MLNP-mediated ID3 mRNA delivery enhanced macrophage phagocytosis, promoted pro-inflammatory immune remodeling, and increased intratumoral T cell and natural killer cell (NK) infiltration, accompanied by tumor-growth suppression. Furthermore, MLNP-ID3 showed enhanced combination activity with anti-PD-1 therapy. Collectively, these findings establish a macrophage-targeted mRNA strategy for transcriptional reprogramming of TAMs and present a promising immunotherapeutic framework for PDAC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Functional Nucleic Acids for Basic and Clinical Application, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.
- Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Functional Nucleic Acids for Basic and Clinical Application, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China; College of Ph…
- Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Functional Nucleic Acids for Basic and Clinical Application, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China. Electronic ad…
Förderung
- Key Research and Development Program of Zhejiang Province
- National Natural Science Foundation of China
- Zhejiang Province Natural Science Foundation
Zitieren
APA
Zhou, W., Wang, H., Li, Y., Zhao, J., Huang, Q., Deng, K., Wang, E., Yang, H., Shi, X., Zhang, J., Jiang, J., & Liu, X. (2026). Reprogramming tumor-associated macrophages via ID3 mRNA delivery for enhanced immunotherapy in pancreatic cancer. Journal of Controlled Release, 400, 115472. https://doi.org/10.1016/j.jconrel.2026.115472
Vancouver
Zhou W, Wang H, Li Y, Zhao J, Huang Q, Deng K, et al. Reprogramming tumor-associated macrophages via ID3 mRNA delivery for enhanced immunotherapy in pancreatic cancer. Journal of Controlled Release. 2026;400:115472. doi:10.1016/j.jconrel.2026.115472
BibTeX
@article{Zhou2026,
author = {Zhou, Wenjing and Wang, Haoyang and Li, Yuting and Zhao, Jun and Huang, Qiang and Deng, Kai and Wang, Erli and Yang, Honghong and Shi, Xiayu and Zhang, Jia and Jiang, Jinhong and Liu, Xiangsheng},
title = {Reprogramming tumor-associated macrophages via ID3 mRNA delivery for enhanced immunotherapy in pancreatic cancer},
journal = {Journal of Controlled Release},
year = {2026},
volume = {400},
pages = {115472},
doi = {10.1016/j.jconrel.2026.115472}
}
EUVIMED